Clinical Trial Update: Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing oral AT1001 with enzyme replacement therapy in Fabry disease has completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• AT1001

Snippet

Sponsor: Amicus Therapeutics | Conditions: Fabry Disease | Phase 3 | Status: COMPLETED | Results posted: 2018-11-01